Roche Sharpens its Focus on Chinese HCV Market with Ascletis Collaboration
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 23 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1927 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Roche has partnered with the US- and China-based speciality pharmaceutical company Ascletis for the development and commercialisation of its hepatitis C virus (HCV) protease inhibitor danoprevir in China...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS